{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:58:55Z","timestamp":1774933135414,"version":"3.50.1"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Amdizalisib (HMPL-689) is an ATP-competitive PI3K\u03b4 inhibitor currently under investigation for treating Hodgkin\u2019s lymphoma. This study aimed to evaluate the metabolism, excretion, pharmacokinetics, and safety profile of amdizalisib in healthy human subjects to support its clinical application.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This Phase I clinical trial included six healthy Chinese male volunteers who received a single oral dose of 30\u00a0mg\/100\u00a0\u00b5Ci [<jats:sup>14<\/jats:sup>C]amdizalisib suspension. Blood, urine, and fecal samples were collected to analyze pharmacokinetics, metabolic pathways, and excretion patterns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Amdizalisib was rapidly absorbed, with a median Tmax of 2.5\u00a0h. The C<jats:sub>max<\/jats:sub> of 244 \u00b1 48.9\u00a0ng\/mL, and AUC<jats:sub>0-t<\/jats:sub> was 1870 \u00b1 474\u00a0h\u00a0ng\/mL after a single oral dose. The blood-to-plasma total radioactivity ratio ranged from 0.561 to 0.645, indicating no significant affinity of [<jats:sup>14<\/jats:sup>C]amdizalisib and its metabolites to blood cells and the radioactive material is mainly distributed in plasma. Excretion was primarily via feces and urine, with 62.08% \u00b1 3.00% and 37.15% \u00b1 2.84% of the dose recovered, respectively, and over 94% of the drug excreted within 96\u00a0h. The parent drug was the main radioactive component in plasma (51.45% of total radioactivity). Additionally, 11 metabolites were identified, and the metabolic pathways include oxidation on the benzene or pyrimidine rings and conjugation with cysteine or glucuronic acid. The major metabolites in plasma were the di-oxidized and hydrogenated product (M424) and the mono-oxidized product (M406-2), accounting for 16.67% and 20.91%, respectively. Both of them are also the major radioactive components in urine and feces, among of which M424 accounted for 21.01% and 14.26%, M406-2 accounted for 8.08% and 11.30%, of the administered dose in urine and feces, respectively. In addition, the di-oxidized and methylated product (M436) was one of the major metabolites in feces accounting for 17.7% of the administered dose. Few of the parent drug was found in urine and feces, suggesting primary metabolized in the liver. No serious adverse events or drug-related deaths occured, with diarrhea as the most common adverse event.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These findings demonstrate that amdizalisib is rapidly absorbed, extensively metabolized, and primarily excreted via feces and urine, supporting its continued development as a potential therapeutic for Hodgkin's lymphoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration:<\/jats:title><jats:p><jats:ext-link>https:\/\/www.chinadrugtrials.org.cn\/<\/jats:ext-link>, identifier CTR20212448.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1478234","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T10:36:42Z","timestamp":1731667002000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Mass balance, metabolism, and pharmacokinetics of [14C]amdizalisib, a clinical-stage novel oral selective PI3K\u03b4 inhibitor for the treatment of non-hodgkin\u2019s lymphoma, in healthy Chinese volunteers"],"prefix":"10.3389","volume":"15","author":[{"given":"Chun-Yang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Sai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Guo","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Ying","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang-Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"J. Am. Soc. Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/hon.3165_653","article-title":"Updated results from a phase 1b study of amdizalisib, a novel inhibitor of phosphoinositide 3\u2010kinase\u2010delta (pi3k\u03b4), in patients with relapsed or refractory lymphoma","volume":"41","author":"Cao","year":"","journal-title":"Hematol. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/fcp.12843","article-title":"Effect of a high\u2010fat meal on the relative bioavailability of HMPL\u2010689 in Chinese healthy volunteers","volume":"37","author":"Cao","year":"","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1124\/dmd.122.001006","article-title":"Human absorption, distribution, metabolism, and excretion studies: origins, innovations, and importance","volume":"51","author":"Cerny","year":"2023","journal-title":"Drug Metab. Dispos."},{"key":"B5","doi-asserted-by":"publisher","first-page":"v448","DOI":"10.1093\/annonc\/mdz251.041","article-title":"A phase I study of HMPL-689, a selective oral phosphoinositide 3-kinase-delta inhibitor, in patients with relapsed or refractory lymphoma","volume":"30","author":"Cohen","year":"2019","journal-title":"Ann. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/psp4.12466","article-title":"The importance of the human mass balance study in regulatory submissions","volume":"8","author":"Coppola","year":"2019","journal-title":"CPT pharmacometrics Syst. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41401-022-00922-6","article-title":"Pharmacokinetics, mass balance, and metabolism of [14C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension","volume":"44","author":"He","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2019-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1021\/js970486q","article-title":"Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening","volume":"87","author":"Hop","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1392209","DOI":"10.3389\/fphar.2024.1392209","article-title":"Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3K\u03b4 inhibitor for the treatment of hematological malignancies","volume":"15","author":"Jiang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12967-018-1710-5","article-title":"Reviewing the role of healthy volunteer studies in drug development","volume":"16","author":"Karakunnel","year":"2018","journal-title":"J. Transl. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1158\/1538-7445.am2020-5234","article-title":"Abstract 5234: A phase I study of HMPL-689, a small molecule selective inhibitor of phosphoinositide 3-kinase-delta, inpatients with relapsed or refractory lymphoma","volume":"80","author":"Lawrence","year":"2020","journal-title":"Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00280-019-03793-7","article-title":"Pharmacokinetics, absorption, metabolism, and excretion of [(14)C]ivosidenib (AG-120) in healthy male subjects","volume":"83","author":"Prakash","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1111\/cts.13403","article-title":"Human radiolabeled mass balance studies supporting the FDA approval of new drugs","volume":"15","author":"Ramamoorthy","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/bcp.13078","article-title":"Pimasertib, a selective oral MEK1\/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients","volume":"82","author":"von Richter","year":"2016","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1478234\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T10:36:48Z","timestamp":1731667008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1478234\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":16,"alternative-id":["10.3389\/fphar.2024.1478234"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1478234","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"article-number":"1478234"}}